Rilapladib Inhibitor

Name: Rilapladib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755457
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755457

Rilapladib is a selective Lipoprotein-Associated Phospholipase A2 inhibitor (IC50: 230 pM). Rilapladib is also a Platelet Activating Factor Receptor antagonist. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Rilapladib, Inhibitor

Full Product Name

Rilapladib

Product Synonym Names

SB 659032

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

735.81

Solubility

DMSO: 86.67mg/mL (117.79mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C40H38F5N3O3S

SMILES

O=C(N(C1CCN(CCOC)CC1)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)CN4C(SCC5=CC=CC(F)=C5F)=CC(C6=C4C=CC=C6)=O

CAS Number

412950-08-4

Target & IC50

Lp-PLA2: ic50 230pM

In Vitro

Rilapladib through reduction of the PAF biological activity and PAF levels to reduce Lp-PLA2 biosynthesis and prevent the possible adverse effects of Lp-PLA2 [2].

Product Categories/Family for Rilapladib, inhibitor

Metabolism; Phospholipase

Product References and Citations for Rilapladib, inhibitor

Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A2 inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094.
Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A2 inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094.
Athanasios Papakyriakou, et al. Computational Investigation of Darapladib and Rilapladib Binding to Platelet Activating Factor Receptor. A Possible Mechanism of Their Involvement in Atherosclerosis. International Journal of Chemistry; Vol. 6, No. 1; 2014.
Athanasios Papakyriakou, et al. Computational Investigation of Darapladib and Rilapladib Binding to Platelet Activating Factor Receptor. A Possible Mechanism of Their Involvement in Atherosclerosis. International Journal of Chemistry; Vol. 6, No. 1; 2014.

Other Notes

Small volumes of Rilapladib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Rilapladib purchase

MBS5755457 is an inhibitor targeting Rilapladib.